Study Review - Real-world analysis of combination induction therapy for Multiple Myeloma

As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a recent study on long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma.

Independent expert commentary is provided by Professor Miles Prince an Australian haematologist and Professor of Medicine at both Melbourne and Monash Universities.

Please login below to download this issue (PDF)